BMY:NYSEBristol-Myers Squibb Company Analysis

Bristol‑Myers Squibb trades at $60.63, just below its 20‑day SMA of $60.92 and comfortably above the 50‑day ($57.67) and 200‑day ($49.85) averages, indicating a lingering bullish bias despite a bearish MACD signal and a modestly negative histogram. The RSI of 54 suggests neutral momentum, while the price sits above the near‑term support at $59.23 and below resistance at $62.89, with a 30‑day volatility of roughly 25% and a low beta near 0.4, pointing to moderate price swings in a generally defensive sector.
Fundamentally, BMY appears undervalued – its DCF‑derived fair value of $62.16 implies a 2.5% upside, and its trailing P/E of 17.5 is well under the industry average of 25.4. The company delivers a robust 4.18% dividend yield with a 72% payout, supported by strong free cash flow ($11.15 B) and a striking 40% ROE, while recent news highlights a “robust growth in its new product portfolio” and renewed hedge‑fund enthusiasm, reinforcing a bullish outlook for medium‑ to long‑term investors.